



## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB/50965001		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/GB99/02241	International filing date (day/month/year) 14/07/1999	Priority date (day/month/year) 14/07/1998	
International Patent Classification (IPC) or national classification and IPC C12N15/52			
Applicant JANSSEN PHARMACEUTICA N.V. et al.			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 9 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input checked="" type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input type="checkbox"/> Certain observations on the international application</li> </ul>			
Date of submission of the demand 18/01/2000		Date of completion of this report 19.12.2000	
Name and mailing address of the International preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 23399 - 0 Tx: 523658 epmu d Fax: +49 89 23399 - 4435		Authorized officer  Wimmer, G  Telephone No. +49 89 23399 7347 	

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB99/02241

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*

Description, pages:

1-63 as originally filed

Claims, No.:

1-48 as originally filed

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/GB99/02241**

*(Any replacement sheet containing such amendments must be referred to under Item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**IV. Lack of unity of Invention**

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
- ☐ paid additional fees.
- ☐ paid additional fees under protest.
- ☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
- ☒ not complied with for the following reasons:  
see separate sheet

4. Consequently, the following parts of the International application were the subject of International preliminary examination in establishing this report:

- ☒ all parts.
- ☐ the parts relating to claims Nos. .

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims 2-4, 6, 8, 11, 13, 14
	No: Claims 1, 5, 7, 9, 10, 12, 15, 18-48
Inventive step (IS)	Yes: Claims
	No: Claims 1-48
Industrial applicability (IA)	Yes: Claims 1-48
	No: Claims

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/GB99/02241

---

2. Citations and explanations  
see separate sheet

**Re Item IV****Lack of unity of invention.**

The present patent application refers to three members of the NAALADase group of peptidases. Specifically, full-length human NAALADase-L, and two previously unidentified members of the gene family, termed NAALADase-II and NAALADase IV, were isolated from human cDNA.

The common technical feature (Rule 13.2 PCT) to the genes and proteins subject of the current application, is that they belong to the family of NAALADases.

This feature, however, does not define a contribution over the prior art, since several members of NAALADases were already defined in the prior art (document D1, abstract; document D2, and references therein). Thus, since the common technical feature of the inventions claimed in the application is not inventive, unity of invention is compromised.

The claims of the current application are therefore regarded as referring to three different inventions:

- I) human NAALADase-L, Claims 1-4, 10-11, as well as (all partially) 9 and 18-48
- II) NAALADase-II, Claims 5-6, 12-14, as well as (all partially) 9 and 18-48
- III) NAALADase-IV, Claims 7-8, 15-17, as well as (all partially) 9 and 18-48

Since, however, the examination of these different inventions poses no excessive effort, no invitation to restrict or to pay additional fees is extended at the moment.

**Re Item V**

**Reasoned statement under Art. 35(2) PCT with regard to novelty, inventive step or industrial applicability.**

The application does not meet the requirements of Art. 33 PCT since claims 1, 5, 7, 9, 10, 12 and 15 are not novel, and claims 1-48 do not appear to contain an inventive step.

- 1) Reference is made to the following documents (the document numbering corresponds to their order of citation in the International search report):  
D1: SHNEIDER, B.L., ET AL.: "Cloning and characterization of a novel peptidase from rat and human ileum." J.BIOL.CHEM., vol. 272, no. 49, 5 December 1997, pages 31006-31015, XP002129302  
D2: LUTHI-CARTER R, ET AL.: "Isolation and characterization of a rat brain cDNA encoding glutamate carboxypeptidase II" PROC.NATL.ACAD.SCI. USA, vol. 95, March 1998, pages 3215-3220, XP002129303

**Novelty.**

- 2) The scope of claim 1 extends to a cDNA molecule encoding human NAALADase-L, or a functional equivalent thereof.

In lack of a precise definition of a function which distinguishes human NAALADase-L from the NAALADases already known in the prior art, a similar function is assumed on the basis of protein homology. Vice versa, the known forms of NAALADase-I (D2, entire document, and references therein), as well as rat NAALADase-L (D1, entire document), can be regarded as functional equivalents of human NAALADase-L.

Since this is comprised in the subject-matter of claim 1, this claim can not be regarded as being novel.

The same applies to the related claim 10, which refers to the human NAALADase-L protein itself, or a functional equivalent thereof.

- 3) For the same reasons, the NAALADases known in the prior art can be regarded as functional equivalents of NAALADase-II and NAALADase-IV. Therefore, claims 5 and 12, and claims 7 and 15, the scope of which extends to functional equivalents of NAALADase-II and NAALADase-IV, respectively, cannot be considered to be novel.
- 4) However, claims 2 - 4 and 11, which refer more specifically to a precise nucleotide or amino acid sequence of human NAALADase-L or splice variants thereof, neither of which have been disclosed entirely in the prior art, can be considered to be novel.

For similar reasoning, claims 6, 13 and 14, and claims 8, 16 and 17, which refer to specific nucleotide or amino acid sequences of human NAALADase-II and human NAALADase-IV, respectively, are regarded as being novel.

- 5) Besides the fact that claim 9 also may depend on the claims 1, 5 and 7, all of which lack novelty, the scope of this claim also lacks a precise definition, since a minimal length of the nucleic acid molecule subject of the claim is not given. It may thus be understood as being limited to a sequence of one or few bases, which have doubtlessly been disclosed in the prior art. This claim therefore also lacks novelty.
- 6) Novelty of the claims 18 - 48 can only be examined if novelty of all claims they depend on has been restored.

Inventive Step.

- 7) The genes and proteins for human, rat and murine NAALADase-I, and for rat NAALADase-L, were known in the prior art. Also, a cDNA fragment encoding roughly half of human NAALADase-L was described.

The technical problem therefore was the identification of new genes and proteins with similar properties.

The obvious solution to the person skilled in the art would be the identification of genes related to the known NAALADases, by sequence comparison and standard cloning techniques.

The solution of the present patent application is the provision of human NAALADase-L, human NAALADase-II and human NAALADase-IV.

The identification of the genes was performed by the inventors as follows:

human NAALADase-L:

- With the sequence information from the prior art, PCR primers for the 3' end of human NAALADase-L were designed.
- PCR was performed using commercially available cDNA as template.
- To obtain the 5' end of the gene, a RACE assay was performed using a standard kit.

human NAALADase-II:

- With all sequence informations on NAALADases from the prior art, BLAST searches on EST databases were performed.
- Positive clones were ordered and sequenced. One of them contained an entire reading frame coding for a protein, which was designated NAALADase-II.

human NAALADase-IV:

- Sequence information from another positive EST clone revealed a partial coding sequence of another NAALADase. This sequence was used in a second BLAST comparison to EST databases.
- The resulting sequence information yielded a contig encoding a protein, which was designated NAALADase-IV. Isolation of the entire gene was performed by PCR.



The isolation of these genes has thus clearly been performed by standard methods used in the field, and was based on sequence information of the known NAALADases.

Since moreover the new NAALADases do not seem to show a surprising effect, the identification and isolation of the genes and proteins therefore lacks an inventive step.

Thus, claims 1-8 and 10-17, which refer to the NAALADases subject of the application, and to the nucleic acids encoding said NAALADases, are regarded as not complying with Art. 33(3) PCT.

- 8) Dependent claims 9 and 18-48 do not contain any features which, in combination with the features of any claim to which they refer, meet the requirements of the PCT in respect of novelty and/or inventive step.

COPY

FIG. 8.

NAALAD I 375 DAQKLLEKXGGSAPPD--SSJRGSLKVPINNVGPGFTGNF---STQKVKEHIHSTNEVTRIYVIGTIRGAVEPDRYVILGG  
NAALAD II 366 DAEILLRYLGGIAPPD--KSWKALNVSISIGPGFTGSD---SFRKVRHVNINKITRIYVIGTIRGAVEPDRYVILGG  
NAALAD L 367 --RDLLCNLNGTLAP--ATUQALGCHRLGPGFRPDGDFPADSQNVSVYNRLRLNSSLULGIRGAVEPDRYVILGG  
NAALAD IV 289 SPHTGQOEYQDGVKPIPTACITVEDAEKHSRASHGK---IVIQLKLGAKTYPDIDS--FNVAAELTCSKYPEQWVILGSG  
APE 3 yeast 313 ---TKHTVATVGVPPKVGKKLIANIALNIDYSLYFANDSYVEFIKTONIADTKHG-DPINIYVILGA  
P96152 199 QITNTIRALSSFNRRFYTTASGAQASDMLANEURSLIS---SLPGSRUEQIKHSGYNQ-KSVULTIOESEXPREDTIVGG  
AMPX vibpr 202 QITGTSSLESFTNRRFYTTTSGAQASDMLIASEUQALS---SLPNASVKKVSHSGYNQ-KSVHNTITCSSEAPDEUWILGG  
APX strgr 84 ---NNGGNR---AHGRPGYKASVDYVYKAKLDAA---GYTTTLAQOFTSGGATG-YNLIANWUPCG-DPNKVLHAGA

NAALAD I 439 HRDSU-VF---G-EI-DPQSG-EAV-VHEIVKVSFGTL-KKEG-URPRRTILFASMDREEFGALGSTETA-EE-NS  
NAALAD II 429 HRDSU-VF---G-AI-DPTSG-VAV-LQETAPSFCKL-HSKG-URPRRTIIFASMDREEFGALGSTETA-EE-NV  
NAALAD L 432 HRDSU-VH---GAV---DPSECTVVL-L-ELSEVUCLLLK-KGTWPPRSIVFASMDREEFGALGSTETA-EEFN  
NAALAD IV 352 HLDSUDV---EQAMDGGG-FFISU-EALSLL---KDLG-LRPERTLRVLVTRNEECGCAFCAY-QLHKV  
APE 3 yeast 375 HSDS---VEE---EPGINDGCTISL-L-NVAKQLTH---FRINNVRFAVMDREEFGALGSTETA-EE-NS  
P96152 270 HLDSU-LGSHTNEQSIAPGADDDASGIESL-S-EIIRVL---RDNN-FRPKRSALNVADEEVGLRGSQDPA-NQYKA  
AMPX vibpr 273 HLDSU-LGSHTNEQSVAPGADDDASGIRAV-T-EVIEVVL---SENN-FQPKRSIATNVADEEVGLRGSQDLA-NQYKS  
APX strgr 147 HLDSU-VSS---GAGINDGSGSAAV-L-ETALLAV---SRAG-FQPDKHLRAVMDREEFGALGSTETA-EE-NS

NAALAD I 516 RLLQERGVAYINASSI-EGNYTLRVDCTPLHYSLVHNLKELKSPDEGFEKGSYESUTTKS--PSPEFSCHPRISKLG  
NAALAD II 506 KILQERSIAYINSSSI-EGNYTLRVDCTPLLYQLVYKLUKEIPSPDDGFEKSKSVESLEKD--PSPENKNLPRINKLG  
NAALAD L 508 KL-QERTVAYINVISV-FANATLRQGPVQSVVFSAMKEIRSPGPGD--LSIVNMGIRYFNRSPPVYGLVPSLGSLS  
NAALAD IV 404 NIS--NYSLVHESGAGT-FLPTGLQFTGSEKARA---INEEUM---SLQPLNITQ-----VLSHG  
APE 3 yeast 435 ENSKIR--VFIDYDYMHA-SPNYEYEDDANKENP--KGEECK---NLVYDYKKAH---HLNYTLVPFDDG  
P96152 327 QGK--KQVSVLQLOHTNYRGSADIDFIDYDTS---NLQOFIT---TIDELVPEL---TYG---YDRCG  
AMPX vibpr 330 EGK--NVVSAQLOHTNYKGSADQVVFIDYDTS---NFQVQVIT---QCHDEFLPSL---TYG---FDTCG  
APX strgr 210 AD-RSLAGYLNFM-IGSPNPGYFYDDDDPVIEK--TFKNYFAG---LNVPTETE---GDGRSDHAPFKN

FIG. 8. (CONTINUED)

NAALAD I	SGNDFEVF	QRL	ELASGRARYT	NUETNKF	SGYPL	YH	SVY	YEL	VEK	----	FYDP	PKYH	LT	V	QVRGG	-----	582								
NAALAD II	SGSDFEAY	QRL	ELASGRARYT	ENKKT	DYSSYP	YH	YH	FEL	VEK	----	FYDP	TKKQ	LS	V	QLRGA	-----	572								
NAALAD L	AGSDYAPF	VHFL	ISSHDI	AYTYDR	SKTSARI	YPT	YH	YH	YH	----	FLDP	GSSH	QAV	RT	AGS	-----	574								
NAALAD IV	EGTDIN	FL	IQAGVPGAS	LLDDL	LYKYFF	-----	FHSH	GDT	MTV	DP	KQHN	VA	AV	SV	VV	DHEEMLPRS	-----	472							
APX 3 yeast	RSDYUGF	INNGIP	AGGIAT	GAETNN	VNNGK	VLDR	CYH	Q	CD	DV	SN	SUD	AF	IT	NT	KLIAH	SVAT	YD	DS	FEG	FPK	RET	QKH	-----	515
P96152	YACSDHAS	GHKAC	FSAA	HPFES	FKDYN	-----	PKI	TS	QD	TL	ANS	SDPT	----	GNH	AVT	TKL	GLAY	VIE	HAN	-----	391				
AMPX vibpr	YACSDHAS	GHNA	CYPAA	HPFES	FNDYN	-----	PRI	HT	QD	TL	ANS	SDPT	----	GSH	AK	Q	TL	GLAY	IE	HGS	-----	394			
APX Strgr	VGVPVGG	LN	GTGA	EYTKS	AAQA	QWGGT	ACQAF	DRCYH	SS	CD	LS	SN	ND	TAL	DRNS	DA	AAHAI	UTL	SS	GT	GE	PPT	-----	284	